Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414290 | 0.88 | NT5E (0.67) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800348 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13190277 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800434 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL223209 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL6312068 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL13134657 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL800395 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL4946500 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 | |
| SCHEMBL7539957 | 0.87 | NT5E (0.65) | NT5ELMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263858-A1 | Process for synthesis of mucin-type peptides and muc1-related glycopeptides | SHIONOGI & CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1801118-A1 | PROCESS FOR SYNTHESIS OF MUCIN-TYPE PEPTIDES AND MUC1-RELATED GLYCOPEPTIDES | SHIONOGI & CO., LTD. (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263858-A1 | Process for synthesis of mucin-type peptides and muc1-related glycopeptides | MUC1, VIP, TMPRSS15 | NT5E 2185/4885LMNA 3839/4885THRB 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.